Left Ventricular Assist Device as Bridge to Recovery for Anthracycline-Induced Terminal Heart Failure

Congestive heart failure (Greenwich, Conn.) Pub Date : 2012-04-22 DOI:10.1111/j.1751-7133.2012.00291.x

Jon M. Appel MD, PHD, Kåre Sander MD, DMSci, Peter B. Hansen MD, Jacob E. Møller MD, PHD, DmSci, Anders Krarup-Hansen MD, PHD, Finn Gustafsson MD, PHD, DMSci

引用次数: 14

Abstract

Anthracycline treatments are hampered by dose-related cardiotoxicity, frequently leading to heart failure (HF) with a very poor prognosis. The authors report a case of a 19-year-old man developing HF after anthracycline treatment for Ewing sarcoma. Despite medical treatment, his condition deteriorated to terminal HF, leading to implantation of a mechanical left ventricular assist device (LVAD). His heart function recovered, allowing explantation of the device 14 months after implantation. Heart transplantation is often contraindicated in the first years after treatment for cancers, and LVAD as “bridge to recovery” may be warranted in similar patients.

Abstract Image

查看原文本刊更多论文

左心室辅助装置作为蒽环类药物致终末期心力衰竭恢复的桥梁

©2012 Wiley期刊，inc .蒽环类药物治疗受到剂量相关心脏毒性的阻碍，经常导致心力衰竭(HF)，预后非常差。作者报告了一例19岁男性在蒽环类药物治疗尤文氏肉瘤后发生心衰的病例。尽管接受了药物治疗，但他的病情恶化为终末期心力衰竭，导致植入机械左心室辅助装置(LVAD)。他的心脏功能恢复了，在植入14个月后可以将该装置移植出去。心脏移植在癌症治疗后的头几年通常是禁忌症，LVAD作为“恢复的桥梁”可能在类似的患者中得到保证。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Congestive heart failure (Greenwich, Conn.)

自引率

0.00%

发文量